Skip to main content
. 2021 Mar 12;10(3):441. doi: 10.3390/antiox10030441

Figure 2.

Figure 2

(A–D) Effects of PG1 at different doses 1 μM (A), 10 μM (B), 50 (C) and 100 μM (D) on angiotensin II-evoked vasoconstriction in mice mesenteric arteries compared to vehicle treated alone. (E) Percentage of reduction of vasoconstriction at different dosage of PG1 (1, 10, 50 and 100 μM). (F) Oxidative stress measured by lucigenin assay on vessels treated with Angiotensin II alone, or ore-incubated with PG1 for 1 h at different doses 1, 10, 50 and 100 μM before Angiotensin II stimulation (10−5). (G) Representative micrographs of Dihydroetidium staining in mesenteric arteries treated with vehicle, with angiotensin-II (10−5) for 30 min of with PG1 (100 μM) plus Angiotensin II. H-I) Vasoconstrictive responses to increasing doses of (H) phenylephrine or (I) noradrenaline, respectively, in basal condition (without stimuli), after PG1 (100 μM) pretreatment, and after pretreatment with PG1 (100 μM) plus Ang II (10−7 M). *, p < 0.05; **, p < 0.001; ***, p < 0.0001.